A detailed history of Opus Capital Group, LLC transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Opus Capital Group, LLC holds 32,700 shares of AVXL stock, worth $282,201. This represents 0.02% of its overall portfolio holdings.

Number of Shares
32,700
Previous 32,700 -0.0%
Holding current value
$282,201
Previous $138,000 34.78%
% of portfolio
0.02%
Previous 0.02%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

BUY
$3.39 - $5.02 $7,458 - $11,043
2,200 Added 7.21%
32,700 $138,000
Q3 2023

Oct 31, 2023

BUY
$6.55 - $9.37 $26,200 - $37,480
4,000 Added 15.09%
30,500 $199,000
Q4 2022

Jan 18, 2023

BUY
$7.65 - $14.43 $76,500 - $144,300
10,000 Added 60.61%
26,500 $245,000
Q3 2021

Oct 29, 2021

BUY
$16.82 - $25.75 $100,920 - $154,500
6,000 Added 57.14%
16,500 $296,000
Q2 2021

Jul 29, 2021

BUY
$10.16 - $28.86 $5,080 - $14,430
500 Added 5.0%
10,500 $240,000
Q3 2020

Oct 30, 2020

BUY
$3.8 - $5.0 $38,000 - $50,000
10,000 New
10,000 $46,000

Others Institutions Holding AVXL

About ANAVEX LIFE SCIENCES CORP.


  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $673M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track Opus Capital Group, LLC Portfolio

Follow Opus Capital Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Opus Capital Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Opus Capital Group, LLC with notifications on news.